Cargando…

Why we should not recommend or offer fluvoxamine to COVID-19 patients?

Detalles Bibliográficos
Autor principal:	Trkulja, Vladimir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780092/ https://www.ncbi.nlm.nih.gov/pubmed/36550263 http://dx.doi.org/10.1007/s00228-022-03447-3

Ejemplares similares

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Reply: Correspondence on Fluvoxamine Treatment of Patients with Symptomatic COVID-19
por: Seo, Hyeonji, et al.
Publicado: (2022)

Extracorporeal Membrane Oxygenation Transport for Severe COVID-19: Why We Can and Should!
por: Mang, Sebastian, et al.
Publicado: (2022)

Why we should abandon the misused descriptor ‘erythema’
por: Finlay, A.Y., et al.
Publicado: (2021)

Why do we fail complying with hand hygiene recommendations in COVID-19 wards?
por: Kuniavsky, Michael, et al.
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Balneotherapy in the era of COVID-19: should it be recommended or not?
por: Guvener, Orhan
Publicado: (2020)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists
por: Khani, Elnaz, et al.
Publicado: (2022)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study
por: Trkulja, Vladimir, et al.
Publicado: (2023)

Critically ill patients with COVID-19: are they hemodynamically unstable and do we know why?
por: Michard, Frederic, et al.
Publicado: (2020)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

COVID-19 and dialysis: why we should be worried
por: Rombolà, Giuseppe, et al.
Publicado: (2020)

Why Are We One-Sided?
por: Janesch, L. V.
Publicado: (1928)

Why Are We One-Sided?
por: Nunan, W.
Publicado: (1928)

Why Are We Right Handed
por: BOUCHE, B. J.
Publicado: (1924)

Why Are We One-Handed
por: Jaensch, L. V.
Publicado: (1924)

COVID-19 lockdown and mental health: why we must look into oncology units
por: Croizier, Carolyne, et al.
Publicado: (2020)

Should We Monitor Pulsus Paradoxus via Pulse Oximetry in Patients with COVID-19 and Acute Respiratory Failure?
por: Michard, Frederic, et al.
Publicado: (2020)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Why should we use convalescent plasma for COVID-19?
por: Franchini, Massimo
Publicado: (2020)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Why We Should Bathe
Publicado: (1888)

What we should focus on and reach out to
por: Nishimura, T.
Publicado: (2023)

Why development of outbreak analytics tools should be valued, supported, and funded
por: Jombart, Thibaut
Publicado: (2021)

“Do no further harm” – Why shall we sedate unresponsive patients?
por: Kalbhenn, Johannes, et al.
Publicado: (2021)

We should not settle for low-level evidence but should always use the best available evidence
por: Narayan, Kailash, et al.
Publicado: (2014)

Why the global health community should support the EndSARS movement in Nigeria
por: Mmonu, Nnenaya A, et al.
Publicado: (2021)

Why should we continue to learn?
por: Golnik, Karl
Publicado: (2017)

The new Surviving Sepsis Campaign recommendations on glucose control should be reconsidered
por: Schultz, Marcus J., et al.
Publicado: (2008)

The recent emergence of Langya henipavirus in China: Should we be concerned?
por: Hanif, Muhammad, et al.
Publicado: (2022)

Downregulation of ACE2 induces overstimulation of the renin–angiotensin system in COVID-19: should we block the renin–angiotensin system?
por: Silhol, François, et al.
Publicado: (2020)

Why we should not ‘just use age’ for COVID-19 vaccine prioritisation
por: Smith, Maxwell J
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i63c020l0g6r71jnh8n29km8o8